In a recent update, JP Morgan has adjusted its price target for 10x Genomics (TXG, Financial), a leader in the genomics field listed on the NASDAQ, reducing it from $12.00 to $9.00. This adjustment reflects a significant decrease of 25% in the anticipated market value of the company's stock.
The revision was made by analyst Rachel Vatnsdal, who continues to maintain a "Neutral" rating for the stock. The rating remains unchanged from the previous evaluation, underscoring a consistent viewpoint on the company's market position. The changes were announced on May 9, 2025, and are denominated in USD.
Investors and stakeholders tracking 10x Genomics (TXG, Financial) are advised to consider these updates in light of their investment strategies and market positions. The maintained "Neutral" rating, despite the lowered price target, suggests a steady outlook for the company's performance in the current economic climate.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 14 analysts, the average target price for 10x Genomics Inc (TXG, Financial) is $14.11 with a high estimate of $26.00 and a low estimate of $7.50. The average target implies an upside of 60.86% from the current price of $8.77. More detailed estimate data can be found on the 10x Genomics Inc (TXG) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, 10x Genomics Inc's (TXG, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for 10x Genomics Inc (TXG, Financial) in one year is $43.13, suggesting a upside of 391.79% from the current price of $8.77. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the 10x Genomics Inc (TXG) Summary page.
